Glenmark's FabiFlu approved for coronavirus treatment in India, costs Rs 103 per tablet.

Coronavirus Vaccine Approved


 Coronavirus Vaccine Approved


Glenmark Pharmaceuticals has introduced the antiviral drug 'Favipiravir' for patients with mild and moderate symptoms of Covid-19. On the other hand, medical experts cautioned that it should not be seen as a panacea for the treatment of corona virus infection. However, he also said that it would be helpful in treatment and would reduce the effects of the virus.


Medical experts said that how effective this drug will be, it will be known in the coming months. Glenmark Pharmaceuticals said it has introduced Favipiravir, an anti-viral drug under the brand name Fibiflu, to treat patients with mild and moderate symptoms of Covid-19. The company said that its price would be around Rs 103 per pill.

coronavirus, Vaccine

A pack of 34 tablets of FabiFlu has been priced at Rs 3,500 (Rs 103 per tablet)


Mumbai-based Glenmark Pharmaceuticals have launched a new antiviral drug - Favipiravir with brand name FabiFlu - for the treatment of mild to moderate Covid-19 patients. The firm has become the first Indian company to commercially launch the antiviral drug. Indian drug regulator Drug Controller General of India (DCGI) gave the company approval for marketing and manufacturing after which the product was launched in the Indian market today.

 

A pack of 34 tablets of FabiFlu has been priced at Rs 3,500 (Rs 103 per tablet). The dosage is 200 mg X 9 tablets on day one and 200 mg X 4 tablets a day for 14 days of the treatment. However, it should only be taken after a doctor's prescription. A clinical trial was conducted by Glenmark among 90 mild and 60 moderate Covid-19 patients across 11 sites in India. The drug is claimed to have an efficacy of over 80% in the treatment of mild to moderate Covid-19 patients.

 

Delhi-based Brinton Pharmaceuticals, Bengaluru-based Strides Pharma, Mumbai-based Lasa Supergenerics and Hyderabad-based Optimus Pharma are some of the other Indian firms that have applied for approval and are readying for its launch in India, according to sources.

 

The active pharmaceutical ingredient (API) and the formulation for FabiFlu were developed by Glenmark through in-house research and development. The DCGI allowed fast track trials with Phase III in limited patients. The approval process is also under Emergency Use Authorisation (EUA).

 

With nearly 13,000 deaths and a fatality rate of 3.28%, India has nearly 4 lakh coronavirus patients as of now. On June 20, 14,516 new cases were reported in the country.